Yuan Yuan1,2,3, Bo Zhou1,2, Shufang Liu3, Yunfeng Wang3, Kundi Wang3, Zhixin Zhang4, Wenquan Niu5. 1. Graduate School, Beijing University of Chinese Medicine, Beijing, China. 2. International Medical Services, China-Japan Friendship Hospital, Beijing, China. 3. Department of Pediatrics, China-Japan Friendship Hospital, Beijing, China. 4. International Medical Services, China-Japan Friendship Hospital, Beijing, China. zhangzhixin032@163.com. 5. Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China. niuwenquan_shcn@163.com.
Abstract
PURPOSES: We aimed to assess the effects of recombinant human growth hormone (rhGH) replacement therapy on metabolic changes by synthesizing data from clinical trials involving children with idiopathic growth hormone deficiency (IGHD). METHODS: Two investigators independently completed literature search, quality assessment, and data extraction. Effect-size estimates are expressed as weighted mean difference (WMD) with 95% confidence interval (CI). RESULTS: A total of 16 clinical trials involving 1319 children were eligible for analysis. Overall analyses showed that total cholesterol was significantly decreased after rhGH replacement therapy (WMD: -0.20 mmol/l; 95% CI: -0.30 to -0.10; p < 0.001), and high-density lipoprotein was significantly increased (WMD: 0.29 mmol/l; 95% CI: 0.24 to 0.33; p < 0.001). Marginal increase was noted for low-density lipoprotein (WMD: -0.22 mmol/l; 95% CI: -0.47 to 0.22; p = 0.092). Subsidiary and meta-regression analyses revealed that length of intervention and sample size were possible causes of heterogeneity. There was a low probability of publication bias. CONCLUSIONS: Our findings indicate an obviously favorable role of rhGH replacement therapy in lipid metabolism in children with IGHD, and this role might be dependent on length of intervention.
PURPOSES: We aimed to assess the effects of recombinant humangrowth hormone (rhGH) replacement therapy on metabolic changes by synthesizing data from clinical trials involving children with idiopathic growth hormone deficiency (IGHD). METHODS: Two investigators independently completed literature search, quality assessment, and data extraction. Effect-size estimates are expressed as weighted mean difference (WMD) with 95% confidence interval (CI). RESULTS: A total of 16 clinical trials involving 1319 children were eligible for analysis. Overall analyses showed that total cholesterol was significantly decreased after rhGH replacement therapy (WMD: -0.20 mmol/l; 95% CI: -0.30 to -0.10; p < 0.001), and high-density lipoprotein was significantly increased (WMD: 0.29 mmol/l; 95% CI: 0.24 to 0.33; p < 0.001). Marginal increase was noted for low-density lipoprotein (WMD: -0.22 mmol/l; 95% CI: -0.47 to 0.22; p = 0.092). Subsidiary and meta-regression analyses revealed that length of intervention and sample size were possible causes of heterogeneity. There was a low probability of publication bias. CONCLUSIONS: Our findings indicate an obviously favorable role of rhGH replacement therapy in lipid metabolism in children with IGHD, and this role might be dependent on length of intervention.
Authors: D Capalbo; A Esposito; R Di Mase; F Barbieri; G Parenti; P Vajro; C Pignata; M Salerno Journal: Minerva Endocrinol Date: 2012-12 Impact factor: 2.184
Authors: Chiara De Leonibus; Stefania De Marco; Adam Stevens; Peter Clayton; Francesco Chiarelli; Angelika Mohn Journal: Horm Res Paediatr Date: 2016-03-10 Impact factor: 2.852